AstraZeneca announces results from interim analysis of Phase 2 ASCEND trial
AstraZeneca announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association Annual Congress in Amsterdam, showing CALQUENCE significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukemia. The ASCEND trial compared CALQUENCE with the investigator's choice of rituximab combined with idelalisib or bendamustine in patients with relapsed or refractory CLL. At a median follow-up of 16.1 months, results from the trial showed a statistically-significant and clinically-meaningful improvement in progression-free survival for patients treated with CALQUENCE versus IdR or BR, reducing the risk of disease progression or death by 69%. The median time without disease progression or death for patients treated with CALQUENCE has not yet been reached versus 16.5 months in the control arm. At 12 months, 88% of patients on CALQUENCE showed no disease progression compared to 68% for the control arm. The safety and tolerability of CALQUENCE was consistent with its established profile. AstraZeneca recently announced that the Phase III ELEVATE-TN trial met its primary endpoint at interim analysis in patients with previously-untreated CLL and that full results will be reported at a forthcoming medical meeting.